[
    [
        {
            "time": "2023-10-01",
            "original_text": "Puma Biotech's sNDA for Nerlynx Combo Gets FDA Acceptance",
            "features": {
                "keywords": [
                    "Puma",
                    "Biotech",
                    "sNDA",
                    "Nerlynx",
                    "FDA",
                    "Acceptance"
                ],
                "sentiment_score": 0.9,
                "policy_related": "true",
                "investment_strategy": "false",
                "sector_focus": [
                    "healthcare",
                    "biotech"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": "none"
            },
            "scores": {
                "Correlation": 10,
                "Sentiment": 9,
                "Importance": 9,
                "Impact": 8,
                "Duration": 7,
                "Entity_Density": 8,
                "Market_Scope": 4,
                "Time_Proximity": 9,
                "Headline_Structure": 8,
                "Source_Recency": 7
            }
        },
        {
            "time": "2023-10-01",
            "original_text": "J&J's Ponesimod Superior to Aubagio in Relapsing MS Patients",
            "features": {
                "keywords": [
                    "J&J",
                    "Ponesimod",
                    "Aubagio",
                    "Relapsing",
                    "MS",
                    "Patients"
                ],
                "sentiment_score": 0.85,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "healthcare",
                    "pharmaceuticals"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": "none"
            },
            "scores": {
                "Correlation": 9,
                "Sentiment": 8,
                "Importance": 8,
                "Impact": 7,
                "Duration": 6,
                "Entity_Density": 7,
                "Market_Scope": 5,
                "Time_Proximity": 8,
                "Headline_Structure": 7,
                "Source_Recency": 6
            }
        },
        {
            "time": "2023-10-01",
            "original_text": "Has Novartis (NVS) Outpaced Other Medical Stocks This Year?",
            "features": {
                "keywords": [
                    "Novartis",
                    "NVS",
                    "Medical",
                    "Stocks",
                    "Outpaced"
                ],
                "sentiment_score": 0.7,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "healthcare",
                    "pharmaceuticals"
                ],
                "causal_factor": "false",
                "causal_impact": "none",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "Correlation": 7,
                "Sentiment": 6,
                "Importance": 7,
                "Impact": 5,
                "Duration": 8,
                "Entity_Density": 6,
                "Market_Scope": 6,
                "Time_Proximity": 7,
                "Headline_Structure": 6,
                "Source_Recency": 5
            }
        }
    ]
]